Press releases

The Microflu4AMR project, based on microfluidic technology and the exploitation of soil microbial diversity, will enable the search and...

Phase II of the antibiotic candidate DNV3837 ongoing – end of the first part of the trial (DSMB) expected mid-2021 Signature of an...

DEINOVE’s Boost-ID project has been selected as part of the “France Relance” plan, a recognition of its strategic positioning. Boost-ID is...

Hervé Ansanay, PhD, former Technology transfer and Business Development Director of the SATT AxLR of Montpellier, is appointed Business...

DEINOVE strengthens its cash position to finance the ongoing clinical trial testing DNV3837 for the treatment of severe gastrointestinal...

Alexis RIDEAU, Deputy Chief Executive Officer of DEINOVE since May 2020, is now the Chief Executive Officer of the Company. Charles WOLER,...

DEINOVE immediately strengthens its cash position to finance the ongoing clinical trial testing DNV3837 for the treatment of severe...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that pioneers the application of biodiversity from the natural environment...

Clinical program for the antibiotic candidate DNV3837 continues, with the support of investigators in the United States AGIR program (...